Form 4: OS Therapies Director Granted 50,000 Stock Options

OS Therapies Inc. Director John Ciccio received a grant of 50,000 stock options with an exercise price of $1.34, vesting in one year.

Summary

• John Ciccio, a Director of OS Therapies Inc. (OSTX), was granted options to purchase 50,000 shares of the issuer's common stock.
• The stock options have an exercise price of $1.34 per share.
• These options were granted on January 22, 2026, and will vest in full on the one-year anniversary of the grant date, provided John Ciccio is still serving as a director.
• The options have an expiration date of January 22, 2036.
• Following this transaction, John Ciccio directly beneficially owns 50,000 derivative securities (stock options).
• John Ciccio also indirectly beneficially owns 435,835 shares of Common Stock through Mill River Partners LLC, where he serves on the board of managers and shares voting and investment power.
• Additionally, John Ciccio directly beneficially owns 20,000 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a routine alignment of director incentives with shareholder value, without indicating any significant operational or financial changes.

Positives

• The grant of stock options to Director John Ciccio aligns his financial interests with the long-term performance and shareholder value of OS Therapies Inc.

Future Outlook

The granted stock options are subject to a one-year vesting period, contingent on John Ciccio's continued service as a director, indicating a future incentive for his ongoing involvement with the company.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a standard practice across industries, serving as a common compensation mechanism to incentivize long-term commitment and align leadership interests with shareholder returns.

Comparison to Industry Standards

• The grant of stock options to a director is a widely accepted compensation practice, comparable to similar equity incentive programs observed in other publicly traded biotechnology and pharmaceutical companies.
• The vesting schedule, tied to continued service, is a typical structure designed to retain key personnel and ensure their ongoing contribution to corporate governance and strategic direction.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with long-term shareholder value, potentially leading to more focused governance and strategic decisions aimed at increasing stock price.

Next Steps

• The 50,000 stock options granted to John Ciccio are scheduled to vest in full on January 22, 2027, provided he remains a director of OS Therapies Inc.

Key Dates

Recommendation

The grant of stock options to a director is a standard compensation practice and does not provide new fundamental information to warrant a change in investment thesis. It primarily serves to align the director's interests with long-term shareholder value, which is generally a positive but not a catalyst for immediate stock price movement.

Keywords

OS Therapies Inc, OSTX, John Ciccio, Stock Options, Director Compensation, Insider Transaction, Beneficial Ownership, Equity Grant